BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 32279316)

  • 1. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
    Simon J; Schroeder L; Ingarfield K; Diehl S; Werner J; Brenner N; Liu Z; Pawlita M; Pring M; Butt J; Ness A; Waterboer T
    Int J Cancer; 2020 Jul; 147(2):461-471. PubMed ID: 32279316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.
    Simon J; Brenner N; Reich S; Langseth H; Hansen BT; Ursin G; Ferreiro-Iglesias A; Brennan P; Kreimer AR; Johansson M; Pring M; Nygard M; Waterboer T
    Cancer Epidemiol; 2022 Apr; 77():102117. PubMed ID: 35121404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: A nationwide study in Finland.
    Ruuskanen M; Irjala H; Minn H; Vahlberg T; Randen-Brady R; Hagström J; Syrjänen S; Leivo I
    Head Neck; 2019 Feb; 41(2):349-357. PubMed ID: 30549170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of human papillomavirus on nasopharyngeal carcinoma in Japan.
    Kano M; Kondo S; Wakisaka N; Moriyama-Kita M; Nakanishi Y; Endo K; Murono S; Nakamura H; Yoshizaki T
    Auris Nasus Larynx; 2017 Jun; 44(3):327-332. PubMed ID: 27499435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a non-endemic eastern european population.
    Svajdler M; Kaspirkova J; Mezencev R; Laco J; Torday T; Dubinsky P; Straka L; Ondic O; Michal M; Skalova A
    Neoplasma; 2016; 63(1):107-14. PubMed ID: 26639240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction.
    Punwaney R; Brandwein MS; Zhang DY; Urken ML; Cheng R; Park CS; Li HB; Li X
    Head Neck; 1999 Jan; 21(1):21-9. PubMed ID: 9890347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
    J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.
    Chang C; Middeldorp J; Yu KJ; Juwana H; Hsu WL; Lou PJ; Wang CP; Chen JY; Liu MY; Pfeiffer RM; Chen CJ; Hildesheim A
    J Med Virol; 2013 Mar; 85(3):524-9. PubMed ID: 23280934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral markers in nasopharyngeal carcinoma: A systematic review and meta-analysis on the detection of p16
    Tham T; Machado R; Russo DP; Herman SW; Teegala S; Costantino P
    Am J Otolaryngol; 2021; 42(1):102762. PubMed ID: 33202328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Value of the Epstein-Barr Virus and p16 Status in Patients with Nasopharyngeal Carcinoma: A Single-Centre Study in Japan.
    Saito Y; Ushiku T; Omura G; Yasuhara K; Yoshida M; Takahashi W; Ando M; Fukayama M; Yamasoba T
    ORL J Otorhinolaryngol Relat Spec; 2016; 78(6):334-343. PubMed ID: 28171876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.